DEFA14A: Aadi Bioscience Appoints David Dornan as Chief Scientific Officer, Bolsters ADC Pipeline

Aadi Bioscience appoints David Dornan as Chief Scientific Officer to advance its newly in-licensed ADC portfolio, coinciding with strategic moves including the sale of FYARRO and a private placement financing.

Summary

• Aadi Bioscience has appointed David Dornan as Chief Scientific Officer.
• Dr. Dornan brings over two decades of experience in oncology drug discovery and development, particularly in antibody-drug conjugates (ADCs).
• This appointment aligns with Aadi's new strategic plan announced in December 2024, which includes selling FYARRO to Kaken Pharmaceuticals for $100 million in cash.
• Aadi is also in-licensing a portfolio of ADCs from WuXi Biologics and securing a $100 million private placement to fund their development.
• Aadi filed its definitive proxy statement on January 31, 2025, for a Special Meeting of Stockholders on February 28, 2025, to vote on the FYARRO sale and financing.
• The company's ADC pipeline targets PTK7, MUC16, and SEZ6.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting a strategic shift towards ADCs, a new CSO appointment, and secured funding. However, the sale of FYARRO introduces some uncertainty.

Positives

• The appointment of an experienced CSO like David Dornan strengthens Aadi's leadership team.
• The sale of FYARRO provides Aadi with $100 million in cash.
• In-licensing a portfolio of ADCs diversifies Aadi's pipeline and focuses on a promising therapeutic area.
• The $100 million private placement provides necessary funding for ADC development.
• The company's ADC pipeline targets PTK7, MUC16, and SEZ6, which could redefine what is possible in cancer treatment.

Negatives

• The company is selling FYARRO and its associated infrastructure, which may impact future revenue streams.
• The company is dependent on the closing of the proposed sale of FYARRO and the PIPE financing.

Risks

• The closing of the FYARRO sale and the private placement are subject to stockholder approval and other conditions.
• Delays in obtaining required approvals from governmental or quasi-governmental entities could impede the transactions.
• Unexpected costs or adverse reactions to business relationships could arise from the transactions.
• The development of ADC assets is subject to preclinical and clinical development risks, including potential delays and failures.
• Aadi may face challenges in obtaining sufficient additional capital to advance its product candidates.
• The company may not realize the anticipated benefits of the FYARRO sale or the private placement.

Future Outlook

Aadi anticipates advancing its ADC portfolio, with potential IND filings and data announcements expected. The company's cash position is expected to improve following the FYARRO sale and private placement, providing a runway for future operations.

Management Comments

• David Lennon, PhD, President and CEO of Aadi Bioscience, stated that David Dornan's experience makes him an ideal leader to advance the company's ADC portfolio.
• David Dornan, PhD, CSO of Aadi Bioscience, expressed excitement about the company's cutting-edge science and commitment to translating innovation into real impact for patients.

Industry Context

The appointment of a CSO with extensive ADC experience and the focus on in-licensing ADC assets reflect the growing importance of ADCs in cancer therapy. The field is undergoing a transformation, and Aadi aims to contribute with a creative tumor-targeting strategy.

Comparison to Industry Standards

• Aadi's strategic shift towards ADCs aligns with industry trends, as companies like Seagen (acquired by Pfizer) and Immunomedics (acquired by Gilead) have demonstrated the potential of ADC therapies.
• The in-licensing of ADC assets from WuXi Biologics is a common practice in the industry, similar to how Elevation Oncology in-licensed ADC assets under Dr. Dornan's leadership.
• The $100 million private placement is comparable to financing rounds seen in other biotech companies focused on developing novel cancer therapies.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the sale of FYARRO, the private placement, and the strategic shift towards ADCs.
• Employees may be affected by the sale of FYARRO and the restructuring of the company.
• Patients may benefit from the development of new ADC therapies.
• Kaken Pharmaceuticals will acquire FYARRO and its associated infrastructure.
• WuXi Biologics will provide ADC assets to Aadi through an in-licensing agreement.
• Investors in the private placement will provide capital to fund ADC development.

Next Steps

• Complete the sale of FYARRO to Kaken Pharmaceuticals.
• Close the private placement financing.
• Advance the development of the in-licensed ADC portfolio.
• Potentially submit IND filings for one or more product candidates.

Key Dates

Keywords

Aadi Bioscience, David Dornan, Chief Scientific Officer, ADC, Antibody-drug conjugates, FYARRO, Kaken Pharmaceuticals, WuXi Biologics, Private placement, Oncology, PTK7, MUC16, SEZ6